Krystal Biotech's CEO is Krish Krishnan, appointed in Jan 2016, has a tenure of 10.5 years. total yearly compensation is $10.44M, comprised of 8.1% salary and 91.9% bonuses, including company stock and options. directly owns 4.92% of the company’s shares, worth €475.57M. The average tenure of the management team and the board of directors is 6.5 years and 7.3 years respectively.
Key information
Krish Krishnan
Chief executive officer
US$10.4m
Total compensation
CEO salary percentage
8.10%
CEO tenure
10.5yrs
CEO ownership
4.9%
Management average tenure
6.5yrs
Board average tenure
7.3yrs
Recent management updates
Recent updates
CEO Compensation Analysis
How has Krish Krishnan's remuneration changed compared to Krystal Biotech's earnings?
Date
Total Compensation
Salary
Company Earnings
Mar 31 2026
n/a
n/a
US$225m
Dec 31 2025
US$10m
US$846k
US$205m
Sep 30 2025
n/a
n/a
US$199m
Jun 30 2025
n/a
n/a
US$147m
Mar 31 2025
n/a
n/a
US$124m
Dec 31 2024
US$16m
US$802k
US$89m
Sep 30 2024
n/a
n/a
US$52m
Jun 30 2024
n/a
n/a
US$106m
Mar 31 2024
n/a
n/a
US$57m
Dec 31 2023
US$6m
US$733k
US$11m
Sep 30 2023
n/a
n/a
-US$30m
Jun 30 2023
n/a
n/a
-US$140m
Mar 31 2023
n/a
n/a
-US$135m
Dec 31 2022
US$3m
US$645k
-US$140m
Sep 30 2022
n/a
n/a
-US$130m
Jun 30 2022
n/a
n/a
-US$115m
Mar 31 2022
n/a
n/a
-US$104m
Dec 31 2021
US$7m
US$581k
-US$70m
Sep 30 2021
n/a
n/a
-US$58m
Jun 30 2021
n/a
n/a
-US$52m
Mar 31 2021
n/a
n/a
-US$43m
Dec 31 2020
US$764k
US$498k
-US$32m
Sep 30 2020
n/a
n/a
-US$27m
Jun 30 2020
n/a
n/a
-US$22m
Mar 31 2020
n/a
n/a
-US$20m
Dec 31 2019
US$631k
US$366k
-US$19m
Compensation vs Market: Krish's total compensation ($USD10.44M) is above average for companies of similar size in the Italian market ($USD6.31M).
Compensation vs Earnings: Krish's compensation has been consistent with company performance over the past year.
CEO
Krish Krishnan (61 yo)
10.5yrs
Tenure
US$10,442,485
Compensation
Mr. Krish S. Krishnan, M.S., M.B.A., is Founder of Krystal Biotech, Inc. since 2016. He has been President, Chief Executive Officer and Chairman at Krystal Biotech, Inc. since 2016. Mr. Krishnan is Co-Owne...
Leadership Team
Name
Position
Tenure
Compensation
Ownership
Krish Krishnan
Founder
10.5yrs
US$10.44m
4.92% € 475.6m
Suma Krishnan
Founder
10.5yrs
US$6.95m
4.98% € 481.4m
Kathryn Romano
Executive VP & Chief Accounting Officer
6.5yrs
US$2.26m
0.076% € 7.3m
John Thomas
EVP, General Counsel & Corporate Secretary
no data
no data
0% € 0
John Karakkal
Vice President of North American Sales & Marketing
no data
no data
no data
Stephane Paquette
Senior Vice President of Corporate Development
no data
no data
no data
Josh Suskin
Senior Director & Head of US Human Resources
no data
no data
no data
Laurent Goux
Executive VP & Head of International
no data
no data
0.0031% € 301.6k
David Chien
Senior Vice President of Clinical Development
4.5yrs
no data
no data
Christine Wilson
Senior VP & Head of US Commercial
less than a year
no data
no data
Trevor Parry
Senior Vice President of Product Development
no data
no data
no data
David Sweet
Director of Clinical Development
no data
no data
no data
6.5yrs
Average Tenure
52yo
Average Age
Experienced Management: 1KRYS's management team is seasoned and experienced (6.5 years average tenure).
Board Members
Name
Position
Tenure
Compensation
Ownership
Krish Krishnan
Founder
10.5yrs
US$10.44m
4.92% € 475.6m
Suma Krishnan
Founder
10.5yrs
US$6.95m
4.98% € 481.4m
Daniel Janney
Lead Independent Director
9.7yrs
US$526.47k
0% € 0
Dino Rossi
Independent Director
9.1yrs
US$491.97k
0.27% € 25.8m
Julian Gangolli
Independent Director
7.3yrs
US$491.47k
0% € 0
E. Sutherland
Independent Director
4.5yrs
US$476.47k
0% € 0
Christopher Mason
Independent Director
5.5yrs
US$468.97k
0% € 0
Catherine Mazzacco
Independent Director
3.3yrs
US$470.97k
0% € 0
Samuel Broder
Chairman of Scientific Advisory Board
6.5yrs
no data
no data
7.3yrs
Average Tenure
61yo
Average Age
Experienced Board: 1KRYS's board of directors are considered experienced (7.3 years average tenure).
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/07/05 02:28
End of Day Share Price
2026/07/03 00:00
Earnings
2026/03/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Krystal Biotech, Inc. is covered by 20 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.